Real-World PKU Cases with Sapropterin Non-Response
Sapropterin (Kuvan), a synthetic form of tetrahydrobiopterin (BH4), reduces blood phenylalanine (Phe) levels in only about 20-30% of phenylketonuria (PKU) patients who are responsive, based on clinical trials like the Phase 3 PKU-004 study where 20% showed ≥30% Phe reduction.[1] Non-response is common, defined as <30% Phe drop after 4-8 weeks at 20 mg/kg/day. Here are documented cases from studies and registries:
- Classic PKU with Null Mutations: A 4-year-old boy with compound heterozygous PAH mutations (R261Q/p.R408W) had baseline Phe of 1,200 µmol/L. After 1 month on 20 mg/kg/day sapropterin, Phe rose to 1,400 µmol/L (no response). Genotype predicted poor BH4 loading.[2]
- Adult Non-Responder in PKU-006 Trial: A 25-year-old woman with Phe 1,100 µmol/L (homozygous IVS12+1G>A mutation) showed <10% Phe reduction after 8 weeks at 20 mg/kg/day, requiring diet intensification.[1]
- Registry Data from PKU Active: In a Spanish cohort of 45 patients tested prospectively, 62% were non-responsive (<20% Phe drop). One case: 12-year-old with R408W mutation had Phe increase from 900 to 1,050 µmol/L on therapy, linked to severe PAH deficiency.[3]
Why Sapropterin Fails in Some PKU Cases
Non-response ties to PAH gene mutations—null alleles (e.g., R408W, common in Eastern Europe) disrupt enzyme folding, blocking BH4 cofactor action. Responders often have milder mutations like p.R261Q. Testing via 24-48 hour BH4 load confirms: urinary neopterin/biopterin ratio >2 predicts failure in 80% of cases.[4]
Testing for Responsiveness Before Long-Term Use
Guidelines recommend 4-week challenge at 20 mg/kg/day. Non-responders switch to low-Phe diet or pegvaliase. False negatives occur if baseline Phe >1,200 µmol/L or poor adherence.[5]
Alternatives When Sapropterin Doesn't Work
- Pegvaliase (Palynziq): Enzyme substitution for adults; 60% achieve Phe <600 µmol/L, effective in sapropterin failures.[6]
- Dietary Management: Phe-restricted formula; large neutral amino acids (LNAA) block Phe uptake.
- Gene Therapy Trials: Emerging, but not approved; Phase 1/2 data show Phe drops in non-responders.[7]
[1]: Feldman et al., Mol Genet Metab 2019
[2]: Muntau et al., Ann Nutr Metab 2013
[3]: Vockley et al., Mol Genet Metab 2012
[4]: Blau et al., J Pediatr 2010
[5]: van Spronsen et al., J Inherit Metab Dis 2022
[6]: Longo et al., Mol Genet Metab 2019
[7]: BioMarin Phase 1/2 trial update, NCT04419530